JP2023537477A - 疾患及び障害を治療するための組成物及び方法 - Google Patents

疾患及び障害を治療するための組成物及び方法 Download PDF

Info

Publication number
JP2023537477A
JP2023537477A JP2023507267A JP2023507267A JP2023537477A JP 2023537477 A JP2023537477 A JP 2023537477A JP 2023507267 A JP2023507267 A JP 2023507267A JP 2023507267 A JP2023507267 A JP 2023507267A JP 2023537477 A JP2023537477 A JP 2023537477A
Authority
JP
Japan
Prior art keywords
compound
subject
pharmaceutical composition
disease
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537477A5 (enExample
Inventor
レメリング，ラインハルト フォン
マルティネス，エリザベス
マーテル，ロバート
Original Assignee
キュリス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュリス，インコーポレイテッド filed Critical キュリス，インコーポレイテッド
Publication of JP2023537477A publication Critical patent/JP2023537477A/ja
Publication of JP2023537477A5 publication Critical patent/JP2023537477A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023507267A 2020-08-03 2021-04-30 疾患及び障害を治療するための組成物及び方法 Pending JP2023537477A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063060413P 2020-08-03 2020-08-03
US63/060,413 2020-08-03
US202063115312P 2020-11-18 2020-11-18
US63/115,312 2020-11-18
PCT/US2021/030192 WO2022031330A1 (en) 2020-08-03 2021-04-30 Compositions and methods for treating diseases and disorders

Publications (2)

Publication Number Publication Date
JP2023537477A true JP2023537477A (ja) 2023-09-01
JP2023537477A5 JP2023537477A5 (enExample) 2024-05-15

Family

ID=80117618

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507267A Pending JP2023537477A (ja) 2020-08-03 2021-04-30 疾患及び障害を治療するための組成物及び方法

Country Status (12)

Country Link
US (1) US20230310444A1 (enExample)
EP (1) EP4188368A4 (enExample)
JP (1) JP2023537477A (enExample)
KR (1) KR20230048358A (enExample)
CN (1) CN116419752A (enExample)
AU (1) AU2021321350A1 (enExample)
BR (1) BR112023001861A2 (enExample)
CA (1) CA3188171A1 (enExample)
CU (1) CU20230009A7 (enExample)
IL (1) IL300310A (enExample)
MX (1) MX2023001296A (enExample)
WO (1) WO2022031330A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3466955T (lt) 2014-01-13 2021-02-25 Aurigene Discovery Technologies Limited Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
EP4319750A4 (en) 2021-04-08 2025-02-26 Curis, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
WO2023172640A1 (en) * 2022-03-08 2023-09-14 X4 Pharmaceuticals, Inc. Treatments for single-mutant waldenström's macroglobulinemia
JP2025516501A (ja) * 2022-05-11 2025-05-30 キュリス，インコーポレイテッド Ｉｒａｋ４修飾化合物による疾患及び障害の治療
WO2024027750A1 (en) * 2022-08-02 2024-02-08 Beigene Switzerland Gmbh Methods of treating pulmonary hypertension using btk inhibitors
WO2025208000A1 (en) * 2024-03-29 2025-10-02 Curis, Inc. Methods of treating cancer in patients with altered protein expression

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502088A (ja) * 2014-01-13 2017-01-19 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体
US20170035881A1 (en) * 2015-10-19 2017-02-09 Acerta Pharma B.V. Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
JP2018514539A (ja) * 2015-04-30 2018-06-07 バイエル ファーマ アクチエンゲゼルシャフト Ｉｒａｋ４の阻害剤とｂｔｋの阻害剤の組み合わせ
WO2019089580A1 (en) * 2017-10-31 2019-05-09 Curis, Inc. Compounds and compositions for treating hematological disorders
JP2020512343A (ja) * 2017-03-31 2020-04-23 アウリジーン ディスカバリー テクノロジーズ リミテッド 血液疾患を処置するための化合物及び組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3800188A1 (en) * 2019-10-02 2021-04-07 Bayer AG Substituted pyrazolopyrimidines as irak4 inhibitors
MX2023005591A (es) * 2020-11-18 2023-05-29 Curis Inc Metodos de tratamiento de enfermedades y trastornos.
EP4319750A4 (en) * 2021-04-08 2025-02-26 Curis, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502088A (ja) * 2014-01-13 2017-01-19 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体
JP2018514539A (ja) * 2015-04-30 2018-06-07 バイエル ファーマ アクチエンゲゼルシャフト Ｉｒａｋ４の阻害剤とｂｔｋの阻害剤の組み合わせ
US20170035881A1 (en) * 2015-10-19 2017-02-09 Acerta Pharma B.V. Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
JP2020512343A (ja) * 2017-03-31 2020-04-23 アウリジーン ディスカバリー テクノロジーズ リミテッド 血液疾患を処置するための化合物及び組成物
WO2019089580A1 (en) * 2017-10-31 2019-05-09 Curis, Inc. Compounds and compositions for treating hematological disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN Y. ET AL., EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 190, JPN6025020204, 25 January 2020 (2020-01-25), pages 112092, ISSN: 0005796911 *
CLINICALTRIALS.GOV ID NCT04278768: "Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukem", DATABASE CLINICALTRIALS.GOV [ONLINE], vol. [検索日：2025年4月1日], JPN6025020205, June 2020 (2020-06-01), ISSN: 0005597603 *
LANDGREN O. ET AL., LEUKEMIA, vol. 28, JPN6025020201, 2014, pages 1799 - 1803, ISSN: 0005597604 *
YOUNES A. ET AL.: "Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NH", BLOOD, vol. 134 (Supplement_1): 5327, JPN6025020203, 2019, ISSN: 0005796910 *

Also Published As

Publication number Publication date
US20230310444A1 (en) 2023-10-05
BR112023001861A2 (pt) 2023-03-07
CA3188171A1 (en) 2022-02-10
CN116419752A (zh) 2023-07-11
CU20230009A7 (es) 2023-09-07
WO2022031330A1 (en) 2022-02-10
EP4188368A4 (en) 2024-09-04
KR20230048358A (ko) 2023-04-11
AU2021321350A1 (en) 2023-03-16
MX2023001296A (es) 2023-02-22
EP4188368A1 (en) 2023-06-07
IL300310A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
JP2023537477A (ja) 疾患及び障害を治療するための組成物及び方法
KR20180113976A (ko) 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법
JP2023550739A (ja) 疾患及び障害を治療する方法
JP2018520352A (ja) アルギナーゼ活性を阻害するための組成物および方法
US12208097B2 (en) Protein kinase C inhibitors for treatment of uveal melanoma
CN113038945A (zh) 细胞因子释放综合征的治疗方法
KR20140072028A (ko) Pi3k- 및 mek-억제제의 상승작용적 조합물
JP2024516353A (ja) がんの治療のための併用療法
JP2025516501A (ja) Ｉｒａｋ４修飾化合物による疾患及び障害の治療
CN121218988A (zh) 治疗未接受bcl2抑制剂的受试者的癌症的方法
CN121398817A (zh) 治疗具有先前免疫检查点抑制剂暴露的受试者的癌症的方法
HK40092945A (zh) 用於治疗疾病和病症的组合物和方法
HK40096682A (zh) 治疗疾病和病症的方法
CN121969366A (zh) 治疗与白介素1β表达降低相关的癌症的方法
EA052069B1 (ru) Способы лечения заболеваний и расстройств
KR20260049608A (ko) 아자 2 고리형 화합물과 항안드로겐제를 사용한 암 병용 요법
WO2025117739A1 (en) Compositions and methods for treating cancer
JP2024542831A (ja) Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法
EA051009B1 (ru) Комбинированная терапия для лечения рака
HK40120966A (zh) 用irak4修饰化合物治疗疾病和病症
BR112019027967A2 (pt) forma b cristalina isolada, composição farmacêutica, método para o tratamento de um distúrbio, método de um composto ou composição, e, processo para produzir forma b cristalina.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230330

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240430

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260217